Erythropoiesis in patients with aggressive and indolent non-Hodgkin's lymphomas.
Parameters of the erythroid, granulocytic, and megakaryocytic hemopoietic stems were compared in 87 patients with aggressive and indolent non-Hodgkin's lymphomas before and 6 months after the start cytostatic therapy. Before chemotherapy anemia was detected in 46% patients with aggressive and 49% patients with indolent lymphomas. Hemoglobin content, peripheral blood erythrocyte count, and total count of erythroid cells in the bone marrow increased during chemotherapy in the indolent lymphoma group. Increased count of erythroid cells in the myelogram was due to decreased count of lymphoid cells in the bone marrow, which was associated with complete or partial remission. In aggressive lymphoma chemotherapy decreased the mean level of hemoglobin and mean erythrocyte count in the peripheral blood, but the total count of erythroid cells in the bone marrow increased; no relationship was detected between lymphocyte count in the bone marrow and erythropoiesis characteristics. Lymphocytosis >50% in the myelogram before chemotherapy was less frequent in this group in comparison with indolent non-Hodgkin's lymphomas.
Domnikova
N P
NP
Institute of Regional Pathology and Pathomorphology, Siberian Division, Russian Academy of Medical Sciences, Novosibirsk. pathol@soramm.ru
Degtyareva
V V
VV
Nepomnyashchikh
L M
LM
D000740:Anemia / Q000097:blood / Q000150:complications; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004906:Erythrocyte Count; D004920:Erythropoiesis; D005260:Female; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000097:blood / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged
D000970:Antineoplastic Agents; D006454:Hemoglobins